Assess whether pediatric studies are necessary or waivable (081b4b)

Situation

The Pharmacovigilance desk packet is 505(b)(2) literature-to-product bridge table after an AdCom briefing document that overstates subgroup findings. Labeling negotiator in a company with a CMC site change mid-review must name Pediatric studies are necessary or Waivable for this Pharma & Life Sciences file. Labeling negotiator in a company with a CMC site change mid-review has to name Pediatric studies are necessary or Waivable for this Pharma & Life Sciences Pharmacovigilance file.

Decision

Labeling negotiator in a company with a CMC site change mid-review must choose Pediatric studies are necessary / Waivable using 505(b)(2) literature-to-product bridge table after an AdCom briefing document that overstates subgroup findings.

Hypotheses to test

• Labeling negotiator can defend Pediatric studies are necessary from 505(b)(2) literature-to-product bridge table after an AdCom briefing document that overstates subgroup findings in a Pharma & Life Sciences challenge.
• Labeling negotiator cannot defend Pediatric studies are necessary from 505(b)(2) literature-to-product bridge table; Waivable is what the extract actually supports after an AdCom briefing document that overstates subgroup findings.
• An AdCom briefing document that overstates subgroup findings never reached the population in 505(b)(2) literature-to-product bridge table — reopen intake, do not close pediatric studies are necessary.
• Two facts in 505(b)(2) literature-to-product bridge table after an AdCom briefing document that overstates subgroup findings conflict for labeling negotiator; hold this Pharmacovigilance file.

Analysis required

• Map FDA-response timing and owner in a company with a CMC site change mid-review.
• Trace CMC, labeling, or pharmacovigilance facts in 505(b)(2) literature-to-product bridge table after an AdCom briefing document that overstates subgroup findings.
• Separate an isolated adverse event from a systemic quality issue.
• For this Pharma & Life Sciences Pharmacovigilance file, read 505(b)(2) literature-to-product bridge table against an AdCom briefing document that overstates subgroup findings and write the one fact that would move pediatric studies are necessary for labeling negotiator.

Recommendation